阿司匹林影响肿瘤血管生成并使人类胶质母细胞瘤内皮细胞对替莫唑胺、贝伐珠单抗和舒尼替尼敏感,损害血管内皮生长因子相关信号传导
本研究使用人原代胶质母细胞瘤内皮细胞,观察阿司匹林对细胞活力、管状结构形成、迁移和血管内皮生长因子释放的影响,并评估其与替莫唑胺、贝伐珠单抗和舒尼替尼联合的效应。结果显示阿司匹林呈剂量依赖性抑制血管生成相关表型,联合治疗具有协同抗癌作用,阿司匹林可降低血管内皮生长因子等相关基因表达。
要点
- 阿司匹林呈剂量依赖性影响胶质母细胞瘤内皮细胞的活力、管状结构形成、迁移和血管内皮生长因子释放。
- 阿司匹林与替莫唑胺、贝伐珠单抗和舒尼替尼联合处理产生协同抗血管生成细胞能力。
- 阿司匹林降低血管内皮生长因子、血管内皮生长因子受体-1、缺氧诱导因子-1α、RAS、丝裂原活化蛋白激酶激酶、AKT和B细胞淋巴瘤2的mRNA表达。
核心结论
- 阿司匹林与抗血管生成治疗在人原代胶质母细胞瘤内皮细胞中显示协同抗癌疗效。
- 作者认为常规化疗联合阿司匹林可能提供对抗肿瘤恶性的新策略。
研究设计与样本
- 研究使用人原代胶质母细胞瘤内皮细胞,观察阿司匹林单独或与替莫唑胺、贝伐珠单抗和舒尼替尼联合的效应。
- 检测指标包括细胞活力、管状结构形成、迁移、血管内皮生长因子产生以及增殖、促血管生成和凋亡调节因子的表达。
主要发现
- 阿司匹林呈剂量依赖性影响胶质母细胞瘤内皮细胞的活力、管状结构形成、细胞迁移和血管内皮生长因子释放。
- 阿司匹林与替莫唑胺、贝伐珠单抗和舒尼替尼联合处理协同对抗促血管生成细胞能力。
- mRNA表达分析显示阿司匹林显著降低血管内皮生长因子、血管内皮生长因子受体-1、缺氧诱导因子-1α、RAS、丝裂原活化蛋白激酶激酶、AKT和B细胞淋巴瘤2的表达,并与替莫唑胺、贝伐珠单抗和舒尼替尼联合显示抗癌效应。
- 缺氧诱导因子-1α、血管内皮生长因子受体-2、Bcl-2相关X蛋白和B细胞淋巴瘤2的蛋白表达水平证实了积极趋势。
临床怎么用
- 作者认为常规化疗联合阿司匹林可能提供对抗肿瘤恶性的新策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma (GBM) is the most common and fatal human brain tumor, with the worst prognosis. The aberrant microenvironment, enhanced by the activation of proangiogenic mediators such as hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF), and their downstream effectors, sustain GBM malignancy. Proangiogenic signaling represents an attractive chemotherapeutic target. Recent evidence suggests a therapeutic benefit from aspirin (acetylsalicylic acid, or ASA) intake in reducing risk and cancer progression. METHODS: In the present study, human primary GBM-endothelial cells (ECs) were used to ascertain whether ASA could inhibit angiogenesis and improve cell sensitivity to drugs. The impact of ASA was observed by measuring cell viability, tube-like structure formation, migration, VEGF production, and proliferative, proangiogenic, and apoptotic modulators expression, such as HIF-1α/VEGF/vascular endothelial growth factor receptor/(VEGFR)-1/VEGFR-2, Ras/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase, phosphoinositide 3-kinase/AKT signaling axis, and Bcl-2-associated X protein/B-cell lymphoma 2 (BCL-2) ratio. Furthermore, we evaluated the effect of ASA alone or in combination with temozolomide (TMZ), bevacizumab (BEV), and sunitinib (SUN). RESULTS: Our data reported that ASA affected GBM-EC viability, tube-like structure formation, cell migration, and VEGF releasing in a dose-dependent manner and that combined treatments with TMZ, BEV, and SUN synergized to counteract proangiogenic cell ability. mRNA expression analysis displayed a marked effect of ASA in reducing VEGF, VEGFR-1, HIF-1α, RAS, mitogen-activated protein kinase kinase, AKT, and BCL-2, as well a combined anticancer effect of ASA together with TMZ, BEV, and SUN. Levels of HIF-1α, VEGFR-2, Bcl-2-associated X protein, and BCL-2 protein expression confirmed a positive trend. CONCLUSIONS: ASA and antiangiogenic therapies showed synergetic anticancer efficacy in human primary GBM-ECs. Thus, the combination of conventional chemotherapy with ASA may offer a new strategy to counteract tumor malignancy.
引用
- Navone SE, Guarnaccia L, Cordiglieri C, et al. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling. World Neurosurg. 2018. PMID: 30144594. doi:10.1016/j.wneu.2018.08.080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。